334300login-checkWhat Evidence Do We Need to Move Forward With COVID Boosters? |
“More data and an evaluation of several factors at home and abroad are key.
On Monday, employees of Pfizer met with high level executives in the Biden administration to discuss the role of boosters — a.k.a. a third vaccination with an mRNA vaccine for SARS-CoV-2. Some have speculated that, as with the first two doses, the emergency use authorization pathway will again be used to market boosters. With the rise of the Delta variant and others, enthusiasm in the media and the Twitter commentariat for boosters is growing. However, there are certain criteria that must be met before we jump on the booster bandwagon. Some of these criteria apply at home, and others apply abroad.”
Learn more, here.
334300login-checkWhat Evidence Do We Need to Move Forward With COVID Boosters? |